Molecular biotechnology firm ThirtyFiveBio has emerged from stealth to present data from its first-in-class small molecule inhibitors of G protein-coupled receptor 35 (GPR35) antagonist program at the upcoming American Association for Cancer Research Annual Meeting 2023. The company had raised USD 20 million in a seed funding round since its inception in 2021 by M:M Bio, in partnership with Canaan Partners. 

The company's focus on GPR35 inhibition is based on preclinical data, which demonstrates that hyperactive genetic mutations within GPR35 contribute to a range of GI disease processes, including inflammatory bowel disease and gastrointestinal (GI) cancers.

UK-based ThirtyFiveBio is a biotechnology company that is focused on developing first-in-class small molecule inhibitors of GPR35 for the treatment of GI disease. It leverages its drug discovery platform to identify potential GPR35 inhibitor targets.